CHINARES PHARMA(HK:03320) Nan Fang Du Shi Bao·2025-08-20 07:15Core Viewpoint - The collaboration between China Resources Pharmaceutical Group and the Nano and Advanced Materials Institute (NAMI) aims to advance the "Nano Delivery Optimization" project for Alzheimer's disease treatment, addressing the growing challenge posed by the increasing number of Alzheimer's patients globally, which has surpassed 50 million [1][3]. Group 1: Collaboration Details - The partnership will leverage NAMI's drug nano-delivery technology and China Resources Pharmaceutical's expertise in pharmaceuticals to enhance drug absorption and treatment efficiency [1][3]. - The collaboration is expected to accelerate the application of nano-delivery technology in Alzheimer's treatment, promoting international scientific research and industrial upgrades [3][4]. - The project focuses on overcoming challenges related to drug absorption and the blood-brain barrier, aiming for breakthroughs from original innovation to industrialization [3][4]. Group 2: Technological Innovations - The collaboration will explore the use of FDA-approved CDK4/6 anti-tumor drugs to inhibit the Pax6 pathway, which links key pathological features of Alzheimer's disease [4][5]. - The partnership will work on advanced technologies such as nano-microsphere carriers and small molecule drug encapsulation to address significant research and development bottlenecks [5]. - The goal is to reduce the dosage of single administrations to minimize adverse reactions, simplify administration protocols to improve patient compliance, and optimize pharmacokinetic characteristics to enhance treatment outcomes [4][5].